Get the Stockscreener App
30.27
2.23%
-0.69
After Hours:
30.29
0.02
+0.07%
Moderna Inc stock is traded at $30.27, with a volume of 6.60M.
It is down -2.23% in the last 24 hours and down -17.18% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$30.96
Open:
$31.18
24h Volume:
6.60M
Relative Volume:
0.64
Market Cap:
$12.16B
Revenue:
$5.06B
Net Income/Loss:
$-2.22B
P/E Ratio:
-5.201
EPS:
-5.82
Net Cash Flow:
$-3.96B
1W Performance:
-10.71%
1M Performance:
-17.18%
6M Performance:
-58.50%
1Y Performance:
-68.16%
1-Day Range:
$30.16
$32.00
1-Week Range:
$30.16
$35.48
52-Week Range:
$29.25
$170.47
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
30.27 | 12.16B | 5.06B | -2.22B | -3.96B | -5.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Genevant and Arbutus File Global Patent Lawsuits Against Moderna - TipRanks
Roivant Sciences Unit, Arbutus File Lawsuits Against Moderna for Alleged Patent Infringement - Marketscreener.com
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna - The Manila Times
Genevant and Arbutus file lawsuits against Moderna - Investing.com India
Genevant Sciences and Arbutus Biopharma File International Lawsuits Against Moderna for Patent Infringement of Lipid Nanoparticle Technology - Nasdaq
Genevant Sciences and Arbutus Biopharma Initiate - GlobeNewswire
Can Arbutus Win Billions? Patent Fight Against Moderna's COVID Vaccine Goes Global - StockTitan
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by John G Ullman & Associates Inc. - MarketBeat
StockWatch: HHS Review of Bird Flu Contract Sinks Moderna Shares - Genetic Engineering & Biotechnology News
Is Moderna Redefining Medicine with Its mRNA Innovations? - Reporteros del Sur -
Moderna (NASDAQ:MRNA) Shares Gap DownTime to Sell? - MarketBeat
National Pension Service Has $21.65 Million Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Why Moderna’s Meteoric Rise is the Talk of 2025: Uncovering Game-Changing Innovations - Jomfruland.net
Moderna receives MHRA marketing authorization for RSV vaccine - Yahoo Finance
Levi & Korsinsky Notifies Moderna, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineMRNA - ACCESS Newswire
Moderna, Inc. (NASDAQ:MRNA) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Y Intercept Hong Kong Ltd Cuts Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Trump administration weighs pulling funding for Moderna bird flu vaccine, Bloomberg News reports - AOL
Moderna Unusual Options Activity - Benzinga
Moderna mRESVIA RSV vaccine approved by MHRA - The Pharma Letter
Moderna's RSV Jab for Adults Secures Regulatory Approval in UK -February 28, 2025 at 11:44 am EST - Marketscreener.com
Moderna Gets UK Marketing Authorization for RSV Vaccine -February 28, 2025 at 10:57 am EST - Marketscreener.com
Moderna Receives Medicines and Healthcare Products Regulatory Agency Marketing Authorization in the UK for RSV Vaccine - ACCESS Newswire
Is Moderna Stock A Sell With RFK Jr. Reportedly Eyeing Funds? - Investor's Business Daily
UK health regulator approves Moderna's RSV vaccine for adults aged 60 and older - Reuters
UK health regulator approves Moderna's RSV vaccine for adults aged 60 and older -February 28, 2025 at 06:09 am EST - Marketscreener.com
UK health regulator approves Moderna's RSV vaccine for people aged 60 and over - TradingView
UK's MHRA Says mRESVIA RSV Vaccine Approved To Protect Patients Aged 60 And Over - Marketscreener.com
3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%. - The Motley Fool
ING Groep NV Takes $1.80 Million Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Opinion: How mRNA Can Help Bridge the Innovation Gap in Rare Disease - BioSpace
Trump admin may nix $590 million Moderna contract for H5N1 shot: Report - NewsBreak
Moderna stresses importance of vaccinations during "quademic" on Coast Live - News 3 WTKR Norfolk
These Stocks Moved the Most Today: Nvidia, Super Micro, Snowflake, Moderna, Tesla, Salesforce, Vistra, and More - Barron's
HHS weighs rescinding Moderna bird flu vaccine contract - Yahoo
Moderna Shares Fall After Reports of HHS Review of Bird Flu Vaccine Contract - The Wall Street Journal
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by D.A. Davidson & CO. - MarketBeat
Health dept. reviewing bird flu vaccine deal with Moderna: RPT - Yahoo Finance
Trump team weighs pulling funds for Moderna Bird Flu Vaccine - Farm Progress
Moderna’s stock stumbles on report HHS is reviewing $590 million award for bird-flu vaccine - MarketWatch
April 11th Options Now Available For Moderna (MRNA) - Nasdaq
Trump Team Weighs Pulling Funds for Moderna Bird Flu Vaccine - Yahoo Finance
Moderna Shares Fall on Report HHS Is Reviewing Bird Flu Vaccine Contract - MSN
Moderna's bird flu vaccine has a problem - Quartz
Moderna Stock Falls on Report HHS Is Reviewing Bird Flu Vaccine Contract - Barron's
Moderna stock falls amid review of bird flu vaccine funds By Investing.com - Investing.com Australia
Moderna stock falls amid review of bird flu vaccine funds - Investing.com
mRNA Vaccine and Therapeutics Market Growth, Trends, - openPR
Handelsbanken Fonder AB Buys 36,697 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Investors in Moderna, Inc. Should Contact Levi & Korsinsky Before October 8, 2024 to Discuss Your RightsMRNA - ACCESS Newswire
Moderna falls after report Trump administration weighs pulling funding for its bird flu vaccine - TradingView
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.45%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):